Effect of Angiotensin-Neprilysin Inhibition (ARNI) on Prognosis of Chronic Heart Failure
A Multicenter, Randomized Controlled Trial of Angiotensin-Neprilysin Inhibition (ARNI) in the Chronic Heart Failure
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Yihui Xiao
- Phone Number: +8613572236467 +86 13572236467
- Email: sbw_514@163.com
Study Contact Backup
- Name: Yihui Xiao
- Phone Number: +8613572236467 +8613572236467
- Email: sbw_514@163.com
Study Locations
-
-
Shaanxi
-
Xi'an, Shaanxi, China, 710000
- Recruiting
- First Affiliated Hospital of Xi'an JiaoTong University
-
Contact:
- Yihui Xiao
- Phone Number: +8613572236467
- Email: sbw_514@163.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥ 18
- HFrEF, defined as LVEF≤40% and New York Heart Association (NYHA) class ≥ II.
- Plasma NT-proBNP ≥ 600 pg/ml, or NT-proBNP ≥ 400 pg/ml if patients have been hospitalized for heart failure in 12 months.
- If patients have been taking ACEI/ARB at recruitment, a stable dose equivalent to at least 10mg/day of enalapril will be required.
- Volunteer for the study and sign the informed consent.
Exclusion Criteria:
- Symptomatic hypotension, systolic blood pressure < 95 mmHg at baseline.
- eGFR < 30 ml(/min*1.73m2) at baseline.
- Serum potassium > 5.4 mmol/L at baseline.
- Contraindication of ACEI or ARB.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Newly diagnosed HFrEF ARNI
Newly diagnosed HFrEF patients will be administered ARNI Entresto according to the clinical condition among the whole study.
|
Sacubitril Valsartan Sodium Tablets, 100mg bid, among whole study
|
|
Active Comparator: Newly diagnosed HFrEF ACEI/ARB
Newly diagnosed HFrEF patients will be administered ACEI/ARB according to the clinical condition among the whole study.
|
Choose one of ACEI/ARB according to the clinical condition among the whole study.
|
|
Experimental: Prior diagnosed HFrEF ARNI
Prior diagnosed HFrEF patients will be administered ARNI Entresto according to the clinical condition among the whole study.
|
Sacubitril Valsartan Sodium Tablets, 100mg bid, among whole study
|
|
Active Comparator: Prior diagnosed HFrEF ACEI/ARB
Prior diagnosed HFrEF patients will be administered ACEI/ARB according to the clinical condition among the whole study.
|
Choose one of ACEI/ARB according to the clinical condition among the whole study.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cardiovascular events
Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months
|
Composite outcomes of all-cause death including cardiac death and re-hospitalization due to heart failure
|
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Six-minutes walking test
Time Frame: Test in 1, 3, 6, 12 months comparing to the baseline.
|
A test evaluating cardiac function.
|
Test in 1, 3, 6, 12 months comparing to the baseline.
|
|
LVEF
Time Frame: Test in 1, 3, 6, 12 months comparing to the baseline.
|
Left ventricular ejection fraction.
|
Test in 1, 3, 6, 12 months comparing to the baseline.
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Director: Yihui Xiao, First Affiliated Hospital Xi'an Jiaotong University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- XJTU1AF-CRF-2018-019
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.